A Phase 2 interventional study of Injectafer and Placebo in Iron Deficiency and Fibromyalgia, sponsored by American Regent, Inc.. Completed at 1 site in United States. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2018-02-20.
Sponsored by American Regent, Inc. (part of Daiichi Sankyo) · Phase 2, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 40 studies testing ferric carboxymaltose in Iron Deficiencies — 8 open to participants now, 8 under way, 2 of them phase 3. ferric carboxymaltose · Iron Deficiencies.
Among the 40 studies testing ferric carboxymaltose in Iron Deficiencies, this one is the 26th largest by enrollment, is one of 2 that started in 2015, is one of 2 in phase 2, and was the 20th registered.
386 studies on the registry are indexed under Iron Deficiencies; 80 are open to participants now.
Browse Iron Deficiencies studies →8 of the 40 studies testing ferric carboxymaltose in Iron Deficiencies are open now, in 7 countries. Recruiting first, the newest first:
Fundación para la Investigación del Hospital Clínico de Valencia · Sites in Spain
Ages 65+
Ziekenhuis Oost-Limburg · Sites in Belgium
Ages 18+
Columbia University · Sites in United States
Ages 10–19
Erasmus Medical Center · Sites in Netherlands
Ages 65+
Tomsk National Research Medical Center of the Russian Academy of Sciences · Sites in Russia
Ages 18+
By country, each count listing its studies:
ferric carboxymaltose: first FDA approval 2013 (INJECTAFER). What it is approved for, and how studies give it, is on its page →
Of the 55 Iron Deficiencies studies recruiting now, 23 (42%) set no upper age limit and 28 (51%) stop at 75 or younger; 15 take children under 18; 16 take healthy volunteers.
This study: 18 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
40 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 2 · Phase 2 3 · Phase 3 15 · Phase 4 18
First in 2007; this study’s year is marked. 2 started in 2015.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 81 is below the median of 99 across 301 interventional studies indexed under Iron Deficiencies.
Median enrollment 134 across the 40 interventional studies. Of the 31 that completed or were terminated, 2 (6%) have results posted.
This tab as a report to print or save as PDF → With an account.
11 of 40 have an industry lead sponsor. The 10 most frequent:
This study is registered under American Regent, Inc., one of the names counted as Daiichi Sankyo. Under that name alone:
American Regent, Inc. is the lead sponsor of 53 studies on the registry; none are open to participants now.
Of its 7 completed or terminated interventional studies of FDA-regulated products, 5 (71%) have results posted.
Daiichi Sankyo has 1 study filed under Iron Deficiencies — fewer than ten, so there is no comparison to draw.
3 of the studies testing ferric carboxymaltose in Iron Deficiencies that are under way reach primary completion within a year, 1 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT07217873Phase 3Columbia UniversityIntraVenous Iron in Kids With Iron Deficiency and Scoliosis Study | 2027-08-31 |
| NCT05793996Tomsk National Research Medical Center of the Russian Academy of SciencesThe Prevalence of Iron Deficiency and the Effectiveness of Ferinject® in Patients With HFpEF (ID-HFpEF) | 2026-12 |
| NCT05759078Wroclaw Medical UniversityEffect of INtravenous FERRic Carboxymaltose Onmortality and Cardiovascular Morbidity, and Quality of Life in Iron Deficient Patients With Recent Myocardial infarCTion | 2026-12-31 |
Add all 3 to your calendar (.ics) → With an account.
Among the 40 studies testing ferric carboxymaltose in Iron Deficiencies, from their registry updates:
Nothing recorded among them since 2026-09-25.
This tab as a report to print or save as PDF → With an account.
This study investigates the efficacy and safety of an IV iron Injectafer in the treatment of iron deficient patients with fibromyalgia. Eligible subjects will be randomized in a 1:1 ratio to receive Injectafer or Placebo on days 0 and 5. All treated subjects will be followed for efficacy and safety for 42 days.
This is a blinded, randomized, placebo-controlled study. All subjects who meet the inclusion requirements and no exclusion criteria will be entered into an up to 14 day screening phase. Eligible subjects will be randomized in a 1:1 ratio to receive Injectafer or Placebo on days 0 and 5. All treated subjects will be followed for efficacy and safety for 42 days. Subjects will visit the clinic on days 0 and 5 for treatment, and then on days 14, 28, and 42. The subject's participation in the study will be for approximately 42 days from day 0.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.
Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.
The protein in red blood cells that carries oxygen. A low level is anemia, which can cause tiredness and breathlessness. Measured in g/dL or g/L (9 g/dL is 90 g/L).
The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.
“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.
Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.
Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.
Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.
After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.
Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.
Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.
The human immunodeficiency virus, which weakens the immune system.
Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Contraception
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hypersensitivity
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Cancer (malignancy)
Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.
Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hemoglobin (Hb)
The protein in red blood cells that carries oxygen. A low level is anemia, which can cause tiredness and breathlessness. Measured in g/dL or g/L (9 g/dL is 90 g/L).
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ULN (upper limit of normal)
The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.
“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hepatitis B tests
Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.
Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hepatitis C tests
Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.
After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ALT and AST (liver enzymes)
Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.
Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
HIV
The human immunodeficiency virus, which weakens the immune system.
Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Investigational drug or device
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
15 mg/kg up to 750 mg undiluted blinded dose of IV Injectafer (ferric carboxymaltose) at 100 mg/minute
Drug: Injectafer
15 cc of Normal Saline IV push at 2 ml/minute
Drug: Placebo
Also known as: Ferric Carboxymaltose (FCM)
Normal saline solution
Also known as: Saline solution
Proportion of Patients With a ≥13 Point Improvement in FIQR Score
The primary efficacy endpoint was the percentage of subjects who had a ≥13-point improvement in the FIQR from baseline to Day 42.
Time frame: Day 42
Change in BPI, Pain Interference
The short version of the Brief Pain Inventory (BPI) includes front and back body diagrams, 4 pain severity items and 7 pain interference items rated on 0-10 scales (with 0 being the best outcome and 10 being the worst outcome), and a question about percentage of pain relief by analgesics. The Pain Interference Score is calculated by adding the scores for the 7 pain interference questions and then dividing by 7 to give a score out of 10.
Time frame: Change from Baseline in Brief Pain Inventory Pain Interference Score at Day 42
Change in FIQR Score
The FIQR has 21 individual questions. All questions are based on an 11-point numeric rating scale of 0 to 10, with 10 being 'worst' and all questions are framed in the context of the past 7 days. The summed score for function (range 0 to 90) is divided by 3, the summed score for overall impact (range 0 to 20) is not changed, and the summed score for symptoms (range 0 to 100) is divided by 2. The total FIQR is the sum of the three modified domain scores.
Time frame: Change from Baseline in FIQR score at Day 42
Change in BPI, Pain Severity
The short version of the Brief Pain Inventory (BPI) includes front and back body diagrams, 4 pain severity items and 7 pain interference items rated on 0-10 scales (with 0 being the best outcome and 10 being the worst outcome), and a question about percentage of pain relief by analgesics. The Pain Severity Score is calculated by adding the scores for the 4 pain severity questions and then dividing by 4 to give a severity score out of 10.
Time frame: Change from Baseline in Brief Pain Inventory Pain Severity Score at Day 42
Change in Fatigue Visual Numeric Scale
Scores range from 0 to 10, with the higher score indicating more fatigue.
Time frame: Change from Baseline in Fatigue Visual Numeric Scale at Day 42
Change in Iron Indices, Serum Ferritin
Time frame: Change from Baseline in Iron Indices, Serum ferritin at Day 42
Change in Iron Indices - Transferrin Saturation
Time frame: Change from baseline in Iron Indices, Transferrin saturation, at Day 42
| Milestone | Injectafer | Placebo |
|---|---|---|
| Started | 41 | 40 |
| Completed | 40 | 39 |
| Not completed | 1 | 1 |
The primary efficacy endpoint was the percentage of subjects who had a ≥13-point improvement in the FIQR from baseline to Day 42.
| Participants | Injectafer | Placebo |
|---|---|---|
| Proportion of Patients With a ≥13 Point Improvement in FIQR Score | 30 | 26 |
The short version of the Brief Pain Inventory (BPI) includes front and back body diagrams, 4 pain severity items and 7 pain interference items rated on 0-10 scales (with 0 being the best outcome and 10 being the worst outcome), and a question about percentage of pain relief by analgesics. The Pain Interference Score is calculated by adding the scores for the 7 pain interference questions and then dividing by 7 to give a score out of 10.
| units on a scale | Injectafer | Placebo |
|---|---|---|
| Change in BPI, Pain Interference | -4.1 ± 3.3 | -2.3 ± 2.6 |
The FIQR has 21 individual questions. All questions are based on an 11-point numeric rating scale of 0 to 10, with 10 being 'worst' and all questions are framed in the context of the past 7 days. The summed score for function (range 0 to 90) is divided by 3, the summed score for overall impact (range 0 to 20) is not changed, and the summed score for symptoms (range 0 to 100) is divided by 2. The total FIQR is the sum of the three modified domain scores.
| units on a scale | Injectafer | Placebo |
|---|---|---|
| Change in FIQR Score | -45.0 ± 29.5 | -29.7 ± 27.0 |
The short version of the Brief Pain Inventory (BPI) includes front and back body diagrams, 4 pain severity items and 7 pain interference items rated on 0-10 scales (with 0 being the best outcome and 10 being the worst outcome), and a question about percentage of pain relief by analgesics. The Pain Severity Score is calculated by adding the scores for the 4 pain severity questions and then dividing by 4 to give a severity score out of 10.
| units on a scale | Injectafer | Placebo |
|---|---|---|
| Change in BPI, Pain Severity | -3.1 ± 2.7 | -1.8 ± 2.1 |
Scores range from 0 to 10, with the higher score indicating more fatigue.
| units on a scale | Injectafer | Placebo |
|---|---|---|
| Change in Fatigue Visual Numeric Scale | -3.7 ± 3.2 | -1.7 ± 2.2 |
| ug/L | Injectafer | Placebo |
|---|---|---|
| Change in Iron Indices, Serum Ferritin | 292.5 ± 145.9 | 2.0 ± 13.8 |
| percent of transferrin saturation | Injectafer | Placebo |
|---|---|---|
| Change in Iron Indices - Transferrin Saturation | 24.4 ± 11.4 | 5.8 ± 15.1 |
Collected over 7 months. Non-serious events are listed at a 0% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Injectafer | 0/41 (0%) | 0/41 (0%) | 16/41 (39%) |
| Placebo | 0/40 (0%) | 0/40 (0%) | 2/40 (5%) |
| Event | Injectafer | Placebo |
|---|---|---|
| FlushingVascular disorders | 6/41 | 0/40 |
| NauseaGastrointestinal disorders | 3/41 | 0/40 |
| DizzinessNervous system disorders | 2/41 | 0/40 |
| Oral herpesInfections and infestations | 0/41 | 1/40 |
| DehydrationMetabolism and nutrition disorders | 0/41 | 1/40 |
| DermatitisSkin and subcutaneous tissue disorders | 1/41 | 0/40 |
| Ear discomfortEar and labyrinth disorders | 1/41 | 0/40 |
| DysgeusiaNervous system disorders | 1/41 | 0/40 |
| HeadacheNervous system disorders | 1/41 | 0/40 |
| ParaesthesiaNervous system disorders | 1/41 | 0/40 |
| Age, Continuous(years) | Placebo | Injectafer | Total |
|---|---|---|---|
| Mean | 44 ± 10.85 | 41 ± 11.07 | 43 ± 10.97 |
| Sex: Female, Male(Participants) | Placebo | Injectafer | Total |
|---|---|---|---|
| Female | 40 | 40 | 80 |
| Male | 0 | 1 | 1 |
| Race/Ethnicity, Customized(Participants) | Placebo | Injectafer | Total |
|---|---|---|---|
| Race — African American | 7 | 7 | 14 |
| Race — Asian | 0 | 1 | 1 |
| Race — Caucasian | 30 | 33 | 63 |
| Race — Hispanic | 2 | 0 | 2 |
| Race — Other | 1 | 0 | 1 |
| History of iron intolerance(Participants) | Placebo | Injectafer | Total |
|---|---|---|---|
| No | 37 | 35 | 72 |
| Yes | 3 | 6 | 9 |
| History of drug allergy(Participants) | Placebo | Injectafer | Total |
|---|---|---|---|
| No | 17 | 21 | 38 |
| Yes | 23 | 20 | 43 |
| IRLS score per Arm/Group(units on a scale) | Placebo | Injectafer | Total |
|---|---|---|---|
| Mean | 16.3 ± 14.9 | 13.4 ± 13.16 | 14.8 ± 14.04 |
Plan to share: Yes
The record gives a start of Mar 2015, a primary completion of Oct 2015 and a completion of Mar 2016. It does not say whether these dates are actual or estimated.
Results were first posted in Dec 2017, 2 years 2 months after primary completion.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Jan 2018. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Ferric carboxymaltose